ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
Rituximab product approval information - Licensing action FDA Accessed on 4 Jan 2012 from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093345.htm.
Rituximab (marketed as Rituxan), Information FDA Accessed on 4 Jan 2012 from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm.
Information for healthcare professionals: Rituximab FDA Accessed on 4 Jan 2012 from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126519.htm.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, et al. N Engl J Med. 2008 Feb 14; 358(7):676-88. PMID: 18272891. Abstract
Chemotherapeutics in the treatment of multiple sclerosis. Kieseier BC, Jeffery DR Ther Adv Neurol Disord. 2010 Sep; 3(5):277-91. PMID: 21179618. Abstract
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Smith MR Oncogene. 2003 Oct 20; 22(47):7359-68. PMID: 14576843. Abstract
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Pescovitz MD Am J Transplant. 2006 May; 6(5 Pt 1):859-66. PMID: 16611321. Abstract
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients Medscape News Accessed on 4 Jan 2012 from http://www.medscape.com/viewarticle/529710_2.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Bar-Or A, Calabresi PAJ, Arnold D, Arnlod D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, et al. Ann Neurol. 2008 Mar; 63(3):395-400. PMID: 18383069. Abstract
Use of rituximab in multiple sclerosis: current progress and future perspectives. Reske D, Haupt WF Expert Rev Clin Immunol. 2008 Sep; 4(5):573-82. PMID: 20476960. Abstract
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, et al. Ann Neurol. 2009 Oct; 66(4):460-71. PMID: 19847908. Abstract
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH Neurology. 2010 Jun 8; 74(23):1860-7. PMID: 20530322. Abstract
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH Arch Neurol. 2010 Jun; 67(6):707-14. PMID: 20558389. Abstract
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Brown BA, Torabi M Drug Saf. 2011 Feb 1; 34(2):117-23. PMID: 21247220. Abstract
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis Genentech, 14 Apr 2008 Accessed on 4 Jan 2012 from http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=11147.
Roche reports positive studies of MabThera given by subcutaneous injection Roche, 8 Dec 2012 Accessed on 10 Dec 2012 from http://www.roche.com/media/media_releases/med-cor-2012-12-08b.htm.
Intas launches biosimilar version of Rituximab Unnithan C, The Times of India, 30 Apr 2013 Accessed on 5 May 2013 from http://timesofindia.indiatimes.com/business/india-business/Intas-launches-biosimilar-version-of-Rituximab/articleshow/19804674.cms.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Axelsson M, Malmeström C, Gunnarsson M, Zetterberg H, Sundström P, Lycke J, Svenningsson A Mult Scler. 2013 May 23. PMID: 23702432. Abstract
Study hints of rituximab MS benefit Gever J, MedPage Today, 3 Jun 2013 Accessed on 8 Jun 2013 from http://www.medpagetoday.com/MeetingCoverage/CMSC-ACTRIMS/39569.
Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E PLoS One. 2013; 8(7):e66308. Epub 2013 Jul 02. PMID: 23843952. Abstract
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Condon MB, Ashby D, Pepper RJ, Cook TH, Levy JB, Griffith M, Cairns TD, Lightstone L Ann Rheum Dis. 2013 Aug; 72(8):1280-6. Epub 2013 Jun 05. PMID: 23740227. Abstract
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder. Kim S-H, Huh S-Y, Lee S J, Joung A, Kim H J JAMA Neurol. 2013 Jul 29. PMID: 23897062. Abstract
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, Sancesario G, Bernardini S, De Angelis G, Martino G, et al. Mult Scler. 2013 Jul 25. PMID: 23886826. Abstract
Efficacy of remission-induction regimens for ANCA-associated vasculitis. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St Clair WE, Fessler BJ, Ding L, et al. N Engl J Med. 2013 Aug 1; 369(5):417-27. PMID: 23902481. Abstract
Roche's MabThera approved for two vasculitis indications in UK Zenopa, 19 Aug 2013 Accessed on 13 Sep 2013 from http://www.zenopa.com/news/801626498/roches-mabthera-approved-for-two-vasculitis-indications-in-uk.
Boxed warning of HBV risk added to Rituxan, Arezerra Medpage Today, 25 Sep 2013 Accessed on 29 Sep 2013 from http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/41864.
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, Skoromets A, Bar-Or A ISRN Neurol. 2013; 2013:748127. Epub 2013 Sep 10. PMID: 24109519. Abstract
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A J Neurol Sci. 2013 Mar 20. PMID: 23522498. Abstract
First proof for rituximab in IgG4-related disease Goodman A, Medscape, 1 Nov 2013 Accessed on 5 Nov 2013 from http://www.medscape.com/viewarticle/813715.
Rituximab for relapsing-remitting multiple sclerosis. He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H Cochrane Database Syst Rev. 2013 Dec 6; 12:CD009130. PMID: 24310855. Abstract
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Kapetanovic MC, Kristensen L-E, Saxne T, Aktas T, Mörner A, Geborek P Arthritis Res Ther. 2014 Jan 2; 16(1):R2. Epub 2014 Jan 02. PMID: 24383620. Abstract
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) ClinicalTrials.gov, 14 Jan 2014 Accessed on 30 Jan 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01212094.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, et al. J Am Soc Nephrol. 2014 Jan 30. PMID: 24480824. Abstract
Roche's new time-saving subcutaneous formulation of MabThera approved in Europe for the treatment of common forms of non-Hodgkin Lymphoma Roche, 28 Mar 2014 Accessed on 1 Apr 2014 from http://www.roche.com/media/media_releases/med-cor-2014-03-28.htm.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Khor C-G, Chen X L-F, Lin T-S, Lu C-H, Hsieh S-C Clin Rheumatol. 2014 Apr 12. Epub 2014 Apr 12. PMID: 24722688. Abstract
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, Kieseier B, Mayatepek E, Hartung H-P, Kuempfel T, et al. Mult Scler. 2013 Jul 25. PMID: 23886825. Abstract
Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg J-E, Chiche L, et al. Ann Intern Med. 2014 Feb 18; 160(4):233-42. PMID: 24727841. Abstract
Rituximab Use in Pediatric Central Demyelinating Disease. Beres SJ, Graves J, Waubant E Pediatr Neurol. 2014 Feb 15. PMID: 24768216. Abstract
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M JAMA Neurol. 2014 Jan 20. PMID: 24445513. Abstract
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy. Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD JAMA Neurol. 2014 May 19. PMID: 24842754. Abstract
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen H-C J Immunol. 2014 Jun 13. PMID: 24928997. Abstract
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. Studer V, Rossi S, Motta C, Buttari F, Centonze D J Neuroimmunol. 2014 Aug 19. PMID: 25175066. Abstract
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. Kim S-M, Park J, Kim S H, Park S-Y, Kim J Y, Sung J-J, Park K S, Lee K-W PLoS One. 2013; 8(12):e82325. Epub 2013 Dec 16. PMID: 24358171. Abstract
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza F M, Pirronti T, Ferraccioli G Semin Arthritis Rheum. 2014 Sep 8. PMID: 25300701. Abstract
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment. Weinfurtner K, Graves J, Ness J, Krupp L, Milazzo M, Waubant E J Child Neurol. 2014 Nov 10. Epub 2014 Nov 10. PMID: 25387545. Abstract
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung H-P, Jarius S, Aktas O BMC Neurol. 2014 Dec 17; 14(1):247. Epub 2014 Dec 17. PMID: 25516429. Abstract
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK Arch Neurol. 2005 Feb; 62(2):258-64. PMID: 15710854. Abstract
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Svenningsson A, Bergman J, Dring A, Vågberg M, Birgander R, Lindqvist T, Gilthorpe J, Bergenheim T Neurol Neuroimmunol Neuroinflamm. 2015 Apr; 2(2):e79. Epub 2015 Feb 26. PMID: 25745637. Abstract
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS) ClinicalTrials.gov, 29 Oct 2012 Accessed on 13 Mar 2015 from https://clinicaltrials.gov/ct2/show/NCT01719159.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E Mult Scler Relat Disord. 2014 Mar; 3(2):244-52. Epub 2013 Oct 25. PMID: 25878012. Abstract
Biogen Idec Becomes Biogen Biogen, 23 Mar 2015 Accessed on 7 Apr 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/biogen-idec-becomes-biogen.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report. Parfenov V, Du Pasquier R, Schluep M Neurologist. 2015 Jun; 19(6):155-7. PMID: 26075469. Abstract
The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. Quan C, ZhangBao J, Lu J, Zhao C, Cai T, Wang B, Yu H, Qiao J, Lu C J Neuroimmunol. 2015 May 15; 282:45-53. Epub 2015 Mar 21. PMID: 25903728. Abstract
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Berger JR, Neltner J, Smith C, Cambi F Mult Scler Relat Disord. 2014 Nov; 3(6):728-31. Epub 2014 Sep 10. PMID: 25891552. Abstract
Rituximab in paediatric onset multiple sclerosis: a case series. Salzer J, Lycke J, Wickström R, Naver H, Piehl F, Svenningsson A J Neurol. 2015 Nov 24. Epub 2015 Nov 24. PMID: 26603152. Abstract
Editors' Pick Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). Rommer P, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, et al. J Neuroimmune Pharmacol. 2015 Nov 20. Epub 2015 Nov 20. PMID: 26589235. Abstract
Editors' Pick Rituximab does not reset defective early B cell tolerance checkpoints. Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E J Clin Invest. 2015 Dec 7. Epub 2015 Dec 07. PMID: 26642366. Abstract
Rituximab: Don't Count It Out as MS Treatment Gever J, MedPage Today, 12 Oct 2015 Accessed on 22 Dec 2015 from http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/54060.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination. Maurer MA, Tuller F, Gredler V, Berger T, Lutterotti A, Lünemann JD, Reindl M J Neuroimmunol. 2016 Jan 15; 290:49-53. Epub 2015 Nov 19. PMID: 26711569. Abstract
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, Nolan M, Appleton R, Leventer RJ, Deiva K, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Feb; 3(1):e188. Epub 2016 Jan 21. PMID: 26819962. Abstract
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, et al. Ann Neurol. 2016 Mar 31. PMID: 27038238. Abstract
Rescue Therapy Using Rituximab for Multiple Sclerosis. Berenguer-Ruiz L, Sempere AP, Gimenez-Martinez J, Gabaldon-Torres L, Tahoces L, Sanchez-Perez R, Diaz-Marin C Clin Neuropharmacol. 2016 Apr 4. PMID: 27046661. Abstract
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Komori M, Lin Y C, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B Ann Clin Transl Neurol. 2016 Mar; 3(3):166-79. Epub 2016 Feb 01. PMID: 27042677. Abstract
The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E Mult Scler Relat Disord. 2016 Mar; 6:49-53. Epub 2016 Jan 19. PMID: 27063622. Abstract
